The activity of lonidamine (a derivative of indazole-carboxylic acid and a new drug with a characteristic antitumor activity) was evaluated In non-small-cell lung cancer (NSCLC). Twenty-five patients with NSCLC with or without prior treatment received lonidamine at the dose of 450 mg/daily p.o. up to progression. Objective responses obtained were: 3 (12%) partial responses and 3 (12%) minor responses with a mean duration of 13.7 weeks for partial responses. Mean duration of treatment was 20 weeks (range 4-97+). During to the drug's characteristics, bone marrow toxicity was not observed; myalgia and mild testicular pain were the most significant side effects.
Get full access to this article
View all access options for this article.
References
1.
BandP.R., DeschampsM., BesnerJ.G., LeclaireR., GervaisP., De SanctisA.J.: Phase I toxicologic study of lonidamine in cancer patients.Oncology, 41, suppl.1: 56–59, 1984.
2.
BandP.R., DeschampsM., BesnerJ.G., LeclaireR., GervaisP., De SanctisA.J.: Phase II study of lonidamine in cancer patients.Oncology, 41(suppl. 1): 66–68, 1984.
3.
BandP.R., MaroundJ., PritchardK., StewartD., CoppinC.M., WilsonK., EisenhauerE.A.: Phase II study of lonidamine in cancer patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trial Group Study.Cancer Treat. Rep., 70: 1305, 1986.
4.
Di SilverioF., TenagliaR., SaragnanoG., CiottoliG.B., De GregorioM., FerraroF.: Lonidamine in carcinoma of the prostate.In: Recent Advances in Chemotherapy, p. 616, IshigamioJ. (Ed.), 1985.
5.
Gallo CurcioC., VenturoI., RinaldiM., Ambesi ImpiombatoF., Del VecchioM.R., TonachellaR., TropeaF., An-tilliA., CiottoliG.B., De GregorioM.: Chemotherapy/radiation therapy plus/minus lonidamine in the treatment of non small cell lung cancer (limited disease).Preliminary results. Semin. Oncol., 15: 26–31, 1989.
6.
HahnG.M., Van KersenI., SilvestriniB.: Inhibition of the recovery from potentially lethal damage by lonidamine.Br. J. Cancer, 50: 657–660, 1984.
7.
HermanekP., SobinL.H.: UICC-TNM classification of malignant tumours.Fourth edition.Springer-Verlag, Tokyo, 1987.
8.
IsraelL., BreauJ.L.: Enhancement of objective responses by lonidamine (LND) in the treatment of NSCLC. Preliminary report. Congr. Naz. Screening in Oncology, 13-15 October, Florence, Italy, 1987.
9.
KimJ.H., AlfieriA., KimS.H., YoungC.W., SilvestriniB.: Radiosensitization of meth-A fibrosarcoma in mice by lonidamine.Oncology, 41(suppl. 1): 36–38, 1984.
10.
KokronO., MacaS., De GregorioM., CiottoliG.B.: Phase II study of lonidamine in non-small cell lung cancer, final report.Br. J. Cancer, 61: 316–318, 1990.
11.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment.Cancer, 47: 207–214, 1981.
12.
PozziE., BernacchiP., FavaC., CiottoliG.B., De GregorioM., BonoA.V.: Phase II study of lonidamine in prostate cancer.Proc. of 14th International Cancer Congress, Budapest, August 21-27, 1986.
13.
PronzatoP., AmorosoD., BertelliG.: Phase II study of lonidamine in metastatic breast cancer.Br. J. Cancer, 59: 251–253, 1989.
14.
ScagliottiG.V., GozzelinoF., AlberaC., PescettiG.: Chronic administration of lonidamine in untreated non small cell lung cancer of stage III.Chemotherapy, 35(1): 64–68, 1989.
15.
Scorza BarcellonaP., CampanaA., SilvestriniB., De MartinoC.: The embryotoxicity of a new class of antisperma-togenic agents: the 3-indazole-carboxylic acids. New Toxicology for Old Arch.Toxicol., suppl.5: 197–201, 1982.
16.
SilvestriniB., CaputoA.: Lonidamine: a new pharmacological approach to the study and control of spermatogenesis and tumours.Chemotherapy27 (suppl. 2): 1–120, 1981.
17.
SilvestriniB., HahnG.M., CioliV., De MartinoC.: Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems.Br. J. Cancer, 47: 221–231, 1983.
18.
WHO Handbook for reporting results of cancer treatment. WHO Offset Publ. No 48, Geneva, WHO, 1979.
19.
YoungC.W., CurrieV.E., KimJ.H., O'HeirM.A., FaragF.M., KinahanJ.E.: Phase I and clinical pharmacological evaluation of lonidamine in patients with advanced cancer.Oncology, 41(suppl. 1): 60–65, 1984.
20.
ZupiG., GrecoC., LaudonioN., BenassiM., SilvestriniB., CaputoA.: In vitro and in vivo potentiation by lonidamine of the antitumour effect of adriamycin.Anticancer Res., 6: 1245–1520, 1986.
